EL-NE-B Methods

Immunization procedure
The immunization procedure for EL-NE-B followed the same procedures as EL-NE with the exception of the Freund's incomplete adjuvant (KLH-CGG-VGAGVPGLGV) which was acquired from Chinese Peptide Company (Beijing, China)
Characterization of clones
The characterization of the EL-NE-B clones was performed similarly to the characterization of the EL-NE clones with the exception of the biotinylated peptide (Biotin-KK-VGAGVPGLGV), the free peptide (VGAGVPGLGV) and the elongated peptide (VGAGVPGLGVG). All used peptides were produced by Chinese Peptide Company (Beijing, China).
EL-NE-B Assay protocol
The EL-NE-B assay protocol followed the EL-NE protocol with the exception of the above-mentioned peptides.
Clinical validation of EL-NE-B
Levels of NE-degraded elastin were determined with the EL-NE-B assay in serum from IPF patients. The diagnosed samples and controls were identical to those investigated with the EL-NE assay in the main manuscript. Additional patient demographics and clinical information is presented in table S1 (See Additional file 2, Appendix 1).
Statistical analyses
The geometric means (95% CI) of the NE-degraded elastin fragments quantified by the EL-NE-B assay, in diagnosed patients, were compared with their respective controls using the two-sided non-parametric Mann Whitney test. All statistical analysis was performed in MedCalc from MedCalc Software (Ostend, Belgium).
Results were considered statistically significant if p < 0.05.
Appendix 2 EL-NE-B Data Reactivity and specificity of EL-NE-B
The inhibition of EL-NE-B, in a competitive ELISA assay, with the free and elongated peptide is presented in Figure S1A . The EL-NE-B antibody was inhibited by the free peptide by 77% but not by the elongated peptide (0%).
EL-NE-B levels were assessed in the in vitro cleavage of human elastin with MMP-2, -7,-9, NE and noncleaved elastin as well as NE alone ( Figure S1B ). EL-NE-B levels in elastin cleaved with NE were over 1700% higher than EL-NE-B levels in the remaining material.
Clinical relevance of EL-NE-B
There was no significant difference in EL-NE-B levels in serum from IPF patients and healthy controls ( Figure S2 ). 
